Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study

Barry Hendin, De Ren Huang, Sibyl Wray, Robert T. Naismith, Sheri Rosenblatt, Javier Zambrano, Brian Werneburg

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach.

METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews.

RESULTS: Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended.

CONCLUSION: The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalNeurodegenerative disease management
Volume7
Issue number1
DOIs
StatePublished - Feb 1 2017

Keywords

  • Delphi
  • adverse event management
  • peginterferon β-1a

Fingerprint Dive into the research topics of 'Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study'. Together they form a unique fingerprint.

  • Cite this